ABSTRACT
INTRODUCTION
Coronary heart disease (CHD) has a multifactorial aetiology involving physiological, environmental and genetic factors, leading to increased susceptibility to atherosclerotic disease
(1) . High-density lipoprotein cholesterol (HDLc) can protect against CHD but the underlying mechanisms are not fully understood. One mechanism is related to the antioxidant properties of HDLc (2) . HDLc appears to protect against oxidation of low-density lipoprotein cholesterol (LDLc) and oxidation of LDLc is important in the initiation and progression of atherosclerosis (3) . The antioxidant effect of HDLc is determined by its enzymes, in particular paraoxonase 1 (PON1) (4) . Paraoxonase-1 (PON1), aryldialkylphosphatase, EC 3.1.8.1, is a plasma enzyme with a molecular mass of 43 kDa. Human plasma PON1 is synthesized in the liver and is a Ca 2+ dependent glycoprotein. PON1 is associated with HDL on which it is almost exclusively located (5) . HDL provide a vector that facilitate secretion of the enzyme by the liver essentially by offering a hydrophobic harbor for the retained signal peptide of the PON1 (6) . Mice lacking PON1 are highly susceptible to atherosclerosis and organophosphate poisoning. In vitro assay showed that PON1 and PON3 inhibit lipid peroxidation in low density lipoprotein, thus reducing level of oxidized lipids which are involved in initiation of atherosclerosis (7) . In human, PON1 gene is located on the long arm of chromosome 7 and has 2 genetic polymorphism, one at position 192 which is gln/Arg substitution (A→G) and the other at position 55 which is a methionine/leucine substitution (A→T). These polymorphisms affect hydrolytic activity of PON1 isoenzymes with respect to lipid peroxidation (5) . However, conflicting results have been reported. Decreased PON1 activity has recently been attributed to be a risk factor for atherosclerotic disease (8) . A low PON1 activity has been, also, observed in CHD patients. As the relationship between altered PON1 activity and Q/R polymorphism in CHD patients is still a matter of controversy and there are no existing data for the Egyptian population, therefore in the present study the distribution of the PON1 192 polymorphisms and its effect on PON1 activity and plasma lipid parameters were examined in Egyptian CHD patients in comparison with healthy controls.
SUBJECTS & MEHODS

Subjects
Patients in the present study were all outpatients attending Cardiology Department, Tanta University Hospital, Tanta, Egypt. All patients had angiography proven CHD, which was visually assessed. All patients had stenosis that was severe enough (more than 60% stenosis) to require intervention either by coronary angioplasty or surgery. No patients had sustained a myocardial infarction within 6 months before taking part in the study. Patients with D.M., renal or hepatic diseases were excluded from the study. 30 patients who fulfilled the inclusion criteria were studied. Fully informed consent were obtained. The control subjects consisted of 30 healthy subjects who either attended a routine health check at a general practice or at their place at work. Lack of coronary artery disease in the control population was assessed by use of a health questionnaire, exercise stress test and all had no history suggestive of coronary artery disease. Subjects with D.M. or renal or hepatic diseases were also, excluded. The demographic details of the patients and controls are shown in table (1). Venous blood was collected from all subjects between 9:00 and 11:00 A.M. after fasting from 10:00-11:00 P.M. the previous day. Sterile K 3 EDTA (tripotassium ethylenediamine tetraacetic acid) coated tubes were used for the DNA extraction samples. Plasma was isolated by low speed centrifugation. White cells were removed from the buffy coat for DNA extraction. Samples were stored at -20 ˚C till the time of use.
Determination of plasma lipids:
Plasma total cholesterol, HDL-C, were determined using CHOD-POD method (Spinreact, Santa Colma, Spain). Plasma triglycerides were measured by the enzymatic GPO-PAP method (Human, Wiesbaden, Germany). LDL-C was estimated using Friedwald formula: LDL-C = total cholesterol -(HDL cholesterol + triglycerides/5) mg/dl DNA was extracted from peripheral leukocytes using standard procedure (Molecular cloning) (11) . Simply, the blood (10 ml) was collected in K 3 EDTA containing sterile tubes and immediately centrifuged at 1300g for 15 minutes at 4 C. The supernatant was removed and by a Pasteur pipette the buffy coat was transferred carefully to another clean tube containing 5 ml lysis buffer [10 mM Tris-Cl (pH 8.0), 0.1 M EDTA(pH 8.0), 0.5% (w/v) Sodium dodecyl sulfate (SDS) % and 20 ng/ml Dnase-free Rnase]. Tubes were incubated for 1 hour at 37 C. Then proteinase K (20mg/ml) was added to final concentration of 100 µg/ml and incubated at 50 C for 3 hours with swirling. Equal volume of phenol equilibrated with 0.1 M Tris-HCl (pH 8.0) was added and shaken gently for 10 minutes. Tubes were centrifuged at 5000g for 15 minutes at room temperature. The aqueous phase was transferred to a clean centrifuge tube and then 0.2 volume of ammonium acetate and 2 volumes ethanol were added and mixed well. DNA was isolated either by centrifugation or by a pipette tip to another tube. Then 1 ml of 70 % ethanol was added and centrifuged for 5 minutes. The tubes were left open until ethanol is evaporated. The DNA was dissolved in a specific volume of TE (pH 8.0) and stored at 4 C. That genomic DNA was used as a template for PCR amplification. Two primers, the sense primer 5`TAT TGT TGC TGT GGG ACC TGA G 3`and antisense primer 5` CAC GCT AAA CCC AAA TAC ATC TC 3`were used for PCR amplification of 99 bp DNA fragment covering the region containing Gln192 or Arg 192. Aliquots of genomic DNA were used for PCR amplification as described previously (5,12) . The PCR reaction mixture contained about 200 ng DNA template, 0.5 M of each primer, 1.5 mM MgCl 2 , 200 M of the 4 dNTP and 1 U Taq DNA polymerase (Amersham, Bioscience). After denaturing the DNA for 4 minutes at 95 C, the reaction mixture was subjected to 35 cycles of denaturing for 1 minute at 95 C, 1 minute annealing at 60 ˚C and 1 minute extension at 72 C. The 99 bp PCR product was digested with 8 U AlwI restriction endonuclease (MBI Fermentas) overnight at 37 C and the digested products were separated by electrophoresis on 2 % agarose electrophoresis and visualized using ethidium bromide. The Arg genotype contains a unique Alw1 restriction site which results in 66 and 33 bp product, whereas the Gln genotype will not be cleaved by this restriction enzyme (figure 1). Table (1) shows age, BMI and basic laboratory parameters of the studied population. Patients were insignificantly different from control as regards body mass index (BMI). However, compared with normal subjects, patients had significantly higher levels of total cholesterol, triglycerides and LDL-C. In contrast HDL-C level was significantly lower in the patient group compared to the control. The PON1 activity was significantly lower in patients with CHD compared with the control group whatever the genotype. PON1 activity was 60 % less in CHD population. 
RESULTS
DISCUSSION
The results of the present study showed that BMI was insignificantly higher in diseased group compared to the control group. This result is in a agreement with that reported by Odawara et al (13) and Aubo et al (14) . However other authors had reported a significant increase in BMI in CHD group compared to the control group (5,15) . The result of lipid profile of the present study confirmed the results of previous reports and went further step to include genotypes and the activity of PON1. The results of the present work showed significant increase in plasma levels of total cholesterol, triglycerides and LDL-C, with significant decrease in plasma levels of HDL-C in patients when compared with the control group ( (14) . Observations of discrepancies between studies may raise some interesting considerations; first, admixture of genetically heterogeneous populations could explain some contradictory results, but it cannot explain the differences found in studies conducted in the same ethnic population, i.e. Caucasians
(1) or Japanese (13) . Second, discrepancies between studies may be due to a bias in patient selection. PON1 192 polymorphism may reflect an underlying unknown mutation responsible for cardiovascular risk located in the same gene or in others. It is, also, conceivable that PON1 192 polymorphism only produces an effect on coronary heart disease risk among particular subgroups of patients in the presence of additional factors that may have different prevalence among populations. In this respect, the possible deleterious effect of PON1 192 polymorphism may be overexpressed when a particular genetic variant and a particular oxidative condition coexist (19) . Among factors which may be associated with increased oxidative risk, dyslipidemic status and diabetes mellitus emerge as firm candidates. Further studies are needed to clarify whether paraoxonase is involved in atherosclerosis by preventing lipid oxidation in the circulation only or there may be other mechanisms linking paraoxonase to CHD.
In the present study the PON1 activity in CHD patients with RR genotype was significantly lower than patients with QQ genotypes (table 3) . This observation confirms the work of Rozek et al (35) . The PONl R allele appears to have a lower capacity to protect against LDL oxidation than the PONl Q allele. One may, in consequence, make a hypothesis that the R allele with low capacity against LDL oxidation may promote 'oxidative stress' and in turn, might increase cardiovascular risk.
The plasma triglycerides were significantly higher in CHD patients with RR genotype compared to QQ genotypes. This results was in accordance with that of Rozek et al (35) . On the other hand Nevin et al (36) and Hegele et al (37) could not find difference in their studies. In the control group there was no significant difference in the lipid profile between different genotypes except the RR genotype which showed a significantly higher level of TG than the QQ type (table 3) . Accumulating evidence indicating that hypertriglyceridaemia (HTG) is a risk factor for cardiovascular disease. This increased risk is probably substantially mediated through the metabolic interrelationships between plasma triglyceride (TG) levels and other risk factors, such as the atherogenic lipid profile (low HDL-C levels and elevated small dense LDL-C levels).
Furthermore, the present study showed positive correlations between LDL-C and plasma total cholesterol and between HLD-C and BMI in CHD group (table 4) . Increasing BMI may be accompanied by increasing food intake especially fat rich food. It is logic to find a positive correlation between LDL-C and total cholesterol because LDL-C has high content of cholesterol and any increase in total cholesterol is accompanied by increase in LDL-C in CHD.
On the other hand, many results showed that the R allele is more dominant in CHD patients
(1,38,39) . In Mexican population the genotype QR was the predominant one followed by the QQ then RR (40) and in Japanese people the R containing genotype is more predominant than the QQ genotype (13) . In Netherlands Leus et al (41) found that the QQ genotype is almost double the R containing genotype and in England, Mackness et al (8) found, also, that the QQ was the predominate genotype in the population.
In conclusion, it is shown that PON1 activities toward paraoxon are lower in subjects with CHD than in control subjects regardless the PON1 genotype although the PON1 activity is much lower in RR genotype than QQ genotype. The number of patients and control subjects analyzed was not large in the present study, so this may be the reason why we could not get significant data about genotype 
